The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

Abstract

INTRODUCTION:

New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introduction of CT-P10 into the European Union (EU) for use in patients with rheumatoid arthritis and cancer diagnoses, using a budget impact analysis model.

METHODS:

The model used a base case scenario in which the 1-year uptake of CT-P10 was estimated at 30%, and the cost of CT-P10 was assumed to be 70% of the cost of RTX. A second 1-year scenario was also modeled, in which the market share of CT-P10 was assumed to be 50% (scenario 2). Finally, 3-year time horizon outcomes were calculated, in which the market share of CT-P10 was assumed to be 30%, 40%, and 50% in the first, second, and third years, respectively.

RESULTS:

In the base case scenario, the introduction of CT-P10 was associated with projected savings of €90.04 million in the first year, which would allow 7531 additional patients to access rituximab treatment. This was equivalent to a 6.4% increase in the number of rituximab-treated patients. In scenario 2, budget savings were €150.10 million, with a total of 12,551 additional patients able to access rituximab, equivalent to a 10.7% increase. Over a 3-year time horizon, projected budget savings were approximately €570 million, equating to 47,695 additional patients able to access rituximab.

CONCLUSIONS:

The model predicted that the introduction of CT-P10 in the EU will be associated with significant budget savings, the reallocation of which will enable many more patients to access rituximab treatment. This is likely to have a significant impact on health gains at patient and societal levels.

FUNDING:

CELLTRION Healthcare Co., Ltd. sponsored the development and analysis of the budget impact analysis model.

• Authors: László Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz, Márta Péntek
• Journal: Advances in therapy (Adv Ther) Vol. 34 Issue 5 Pg. 1128-1144 (05 2017) ISSN: 1865-8652 [Electronic] United States
• PMID: 28397080 (Publication Type: Comparative Study, Journal Article, Multicenter Study)

Chemical References

• Antibodies, Monoclonal
• Biosimilar Pharmaceuticals
• Rituximab

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (economics, therapeutic use)
• Arthritis, Rheumatoid (drug therapy, economics)
• Biosimilar Pharmaceuticals (economics, therapeutic use)
• Cost Savings
• Europe
• Female
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, economics)
• Lymphoma, Non-Hodgkin (drug therapy, economics)
• Male
• Middle Aged
• Rituximab (economics, therapeutic use)